Разработка и регистрация лекарственных средств (Mar 2024)
Development and Validation of an HPLC-MS/MS Method for the Quantitative Determination of Etmaben in Human Blood Plasma
Abstract
Introduction. Etmaben is a promising drug for the treatment of cardiovascular diseases, widely studied in preclinical studies. In order to conduct phase I clinical trials, it is necessary to develop a bioanalytical method for the quantitative determination of etmaben in human blood plasma.Aim. The aim of the study is to develop and validate a method for the quantitative determination of etmaben in human blood plasma using high-performance liquid chromatography with tandem mass spectrometric detection (HPLC-MS/MS) for the pharmacokinetic study.Materials and methods. The determination of etmaben in human blood plasma was carried out on a Nexera XR chromatograph with a mass-selective detector LCMS-8040 (Shimadzu Corporation, Japan). Sample preparation: precipitation with acetonitrile. Internal standard: promethazine. Column: Luna C18, 100 Å, 50 × 2.00 mm, 5 µm. Elution in gradient mode at a flow rate of 1.00 mL/min. Mobile phase: 0.1 % formic acid solution in water (eluent A), 0.1 % formic acid solution in acetonitrile (eluent B). Retention time for etmaben and promethazine is approximately 1.18 min and 1.15 min, respectively. Total chromatogram registration time: 4.00 min. Ionization method and mode: electrospray; negative mode for etmaben, positive mode for promethazine. Detection was carried out in the mode of multiple reaction monitoring (MRM): 249.90 → 92.15 m/z; 249.90 → 160.20 m/z (etmaben); 284.95 → 197.95 m/z (promethazine).Results and discussion. We have developed, for the first time, a method for determining etmaben and performed its full and partial validation according to current regulatory requirements.Conclusion. The method for determining etmaben in human blood plasma with a confirmed analytical range of 0.250–30.000 µg/mL has been developed and validated. The confirmed analytical range of the method based on the results of the partial validation was 0.040–35.000 µg/mL. The method was successfully applied in phase I clinical trials and can be used for other pharmacokinetic studies of etmaben.
Keywords